{"basic_info": {"ticker": "300204", "exchange": "XSHE", "bloomberg_ticker": "300204 CH Equity", "name": "STAIDSON BEIJING BIOPHARMA-A", "industry": "Biotechnology", "name_chinese_simplified": "舒泰神", "period": "2020", "market_value": 4274790144, "total_income": 165982292, "ccy": "人民币元", "shariah_compliance_summary": "compliant"}, "business_activity_screening": {"summary": [{"shariah_compliance": "compliant", "income": 163850101, "business_income_over_total_income": 0.9871541055716956}, {"shariah_compliance": "unknown", "income": 2132190, "business_income_over_total_income": 0.012845888403565363}], "details": [{"business_activity_cn": "注射用鼠神经生长因子（苏肽生）", "business_activity_en": "Injection mouse nerve growth factor (Su peptide Health)", "income": 53875190, "business_income_over_total_income": 0.3245839622458039, "shariah_compliance": "compliant"}, {"business_activity_cn": "复方聚乙二醇电解质散（IV）（舒泰清）", "business_activity_en": "Polyethylene glycol Electrolyte Powder Compound (IV) (Shutai Qing)", "income": 109974911, "business_income_over_total_income": 0.6625701433258917, "shariah_compliance": "compliant"}, {"business_activity_cn": "合计特别调整", "business_activity_en": "Total special adjustments", "income": 2132190, "business_income_over_total_income": 0.012845888403565363, "shariah_compliance": "unknown"}]}, "financial_screening": [{"item": "Debt to Market Capitalization", "amount": 0.011316590956912093, "shariah_compliance": "compliant", "amount_over_market_value": 0.011316590956912093}]}